(NewsDirect)
Learn More aboutSciSparc Ltd. by gaining access to the latest researchreport
Thereis a high probability that you may know someone battling some form ofaddiction. Whether it’s a problem with opioids, alcohol, cocaine, oreven using pain meds, an unchecked addiction can be fatal.
Addiction, or substanceuse disorder (SUD), can be a chronic mental health condition thatdemands urgent attention before it gets out of hand.
Take alcohol abuse, forexample; the WorldHealth Organization (WHO) estimates that three million deathsyearly result from the harmful use of alcohol. This represents 5.3% ofall deaths.
Overall, 5.1% of the global burden of disease and injury isattributable to alcohol, as measured in disability-adjusted life years(DALYs).
Lookingat the overall drug abuse and addiction globally, around 275 millionpeople used drugs worldwide in 2020, while over 36 million peoplesuffered from drug use disorders, according to the 2021World Drug Report by the United Nations Office on Drugs andCrime (UNODC).
Zooming into the U.S., the National Center for DrugAbuse Statistics (NCDAS) estimates that nearly half of allpeople 12 and older in the U.S. have used an illicit substance atleast once. Since 2000, almost one million people have died of a drugoverdose.
Thesestaggering statistics call for effective therapies and treatmentcenters to help curb the trend, especially as there are indicationsthat the number of drug users worldwide is likely to climb up to 11%by 2030.
Risingawareness about the adverse effects of alcohol and substance abuse,the introduction of new therapies, and increasing rehabilitationcenters are expected to fuel the growth of the global substance abusetreatment market.
The global substance abuse treatment market was valued at $10.2 billion in 2021 and is projected to grow at a compound annualgrowth rate (CAGR) of 8.5% from 2022 to 2031. The market isanticipated to cross $23.1 billion by 2031.
Pharmaceutical companieslike Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), ViatrisInc. (NASDAQ: VTRS), SciSparc Ltd. (NASDAQ: SPRC), and BioCorRx Inc. (OTCMKTS: BICX) are advancing research andtherapies aimed at serving the needs of the market.
SciSparc is a specialtyclinical-stage pharmaceutical company focused on developing therapiesto treat CNS disorders from a portfolio of technologies and assetsbased on cannabinoid pharmaceuticals.
The company is engaged in drug development programsbased on tetrahydrocannabinol (THC) and nonpsychoactive cannabidiol(CBD).
Thecompany’s pipeline ofproduct candidates includes SCI-110 for treating Tourette syndrome,Alzheimer’s disease and agitation; SCI-160 for treating pain; andSCI-210 for treating autism spectrum disorder and statusepilepticus.
Italso has CannAmide™, an immediate unique palmitoylethanolamide (PEA)oral formulation for reducing chronic pain andinflammation.
Positive Results For Psychedelic CombinationTreatment
InMay this year, SciSparc announced positive efficacy and safety profile results from its jointpreclinical trial with Clearmind Medicine Inc. (NASDAQ:CMND,CSE: CMND)), a psychedelic pharmaceutical company focusedon the discovery and development of novel psychedelic-derivedtherapeutics to solve widespread and underserved healthproblems.
Thetrial tested the proprietary combination of SciSparc’s CannAmide™with Clearmind’s psychedelic molecule5-Methoxy-2aminoindane ( MEAI ) forsuppressing alcohol use disorder.
A histopathology assessment was conducted onseveral organs (heart, lungs, liver, kidneys, brain, pancreas, spleenand thyroid gland) from all experiment groups to determine the safetyof the proprietary combination of MEAI and CannAmide™ versus controlmice that were not exposed to alcohol.
Previously announced successful results showeda significant dose-dependent effect for the MEAI treatment in reducingalcohol consumption in treated animals, with substantial additionaleffect when combining CannAmide™ with the lower sub-effective MEAIdose.
On Aug. 24,the company announced additional positive preclinical results of its psychedelic-basedpharma collaboration for treating cocaine addiction using MEAI.
These preclinical studyresults add to the company’s collaboration with Clearmind for its combinationtreatment for various addictions, including preclinicalstudies results and filing two provisional patent applications relatedto compositions comprising MEAI and n-acylethanolamines, their use andtreating cocaine addiction.
Gal Yadid and his team from the GondaMultidisciplinary Brain Research Center at Bar Ilan University inIsrael led a preclinical trial designed to evaluate the possiblereward-like effects of MEAI in connection to cocaine and its abilityto abolish cocaine- inducedconditioned place preference .
The self-administration paradigm, the gold-standardmodel for examining drug addiction, was used in the preclinical trial.Rats were catheterized and trained to self-administer cocaine.
The results identified astatistically significant sub-group that responded dramatically to thetreatment, significantly decreasing the craving for cocaine comparedto a nontreated control group.
Follow the story at SciSparc’s website here .
SciSparc Ltd.is a specialty clinical-stage pharmaceutical company led by anexperienced team of senior executives and scientists. SciSparc'sfocus is on creating and enhancing a portfolio of technologies andassets based on cannabinoid pharmaceuticals. With this focus, theCompany is currently engaged in the following drug developmentprograms based on THC and/or non-psychoactive cannabidiol (CBD):SCI-110 for the treatment of Tourette Syndrome, for the treatment ofAlzheimer's disease and agitation; SCI-160 for the treatment ofpain; and SCI-210 for the treatment of autism spectrum disorder andstatus epilepticus.
This post contains sponsoredadvertising content. This content is for informational purposes onlyand is not intended to be investing advice.
ContactDetails
TraDigital IR- Christine Petraglia
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.